SBIR PHASE I: Method for Isolating Catalytic Antibodies

SBIR 阶段 I：分离催化抗体的方法

• 批准号: 9560457
• 负责人: Jan Trnovsky
• 金额: $ 7.5万
• 依托单位: ONE CELL SYSTEMS, INC
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 1996
• 资助国家: 美国
• 起止时间: 1996-02-01 至 1996-12-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=9560457&HistoricalAwards=false
• 关键词: SBIR; PHASE; Method; Isolating; Catalytic

This Small Business Innovation Reseach Phase I project is addressed toward the isolation of antibodies which demonstrate catalytic properties by encapsulating cells in gel microdrops and analyzing using flow cytometry. Fluorescent products will be retained within the agarose microsphere and cells of interest can be recovered for cloning or gene analysis using fluorescent activated cell sorting. Successful completion of Phase I studies will lead to development of a rapid, automated method for isolating, analyzing and recovering cells producing antibodies of interest. This novel technology can be adapted as a back end screen for recombinant and chemical libraries currently used in a wide array of applications. Catalytic antibodies can be used to produce a virtually inexhaustible source of biocatalysts. The ability to generate specific proteases would have a significant impact on biotechnology and medicine for use as therapeutics as well as industrial enzymes. The total estimated worldwide market for catalytic antibodies is estimated to be in excess of $ 1.0 billion.

这个小型企业创新研究第一阶段项目是针对抗体的分离，这些抗体通过将细胞封装在凝胶微滴中并使用流式细胞术进行分析来展示催化特性。 荧光产物将保留在琼脂糖微球内，并且可以回收感兴趣的细胞用于使用荧光激活的细胞分选进行克隆或基因分析。 I期研究的成功完成将导致开发用于分离、分析和回收产生感兴趣抗体的细胞的快速、自动化方法。 这种新技术可适用于目前广泛应用的重组和化学文库的后端筛选。 催化抗体可用于产生几乎取之不尽的生物催化剂。 产生特定蛋白酶的能力将对用作治疗剂以及工业酶的生物技术和医学产生重大影响。 催化抗体的全球市场估计总额超过10亿美元。